
Ajanta Pharma (AJANTPHARM) Share Price Fall Streak Extends to Second Straight Session
Updated: 5 Oct 2026 • 12:55 pm
Posted by:

Ajanta Pharma Share Price Fall Streak has now run into a second straight session, with the stock last traded at Rs 3,499.75, down 2.3% for the day, and the company valued at Rs 44,762.82 crore. The price move is confirmed in Univest data; a company-specific reason has not been established.
The pattern matters because a two-session decline gives a different read from a single-day dip. Ajanta Pharma Share Price Fall Streak is now being viewed against a lower base price of Rs 3,617.45 from 01 October 2026, so the cumulative move is more relevant than any one intraday swing. For readers tracking Ajanta Pharma Share Price, the question is whether the latest lower close changes valuation positioning, sector comparison and peer context rather than just the day move.
Ajanta Pharma (AJANTPHARM) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 3,499.75 |
| Previous Close | Rs 3,582.2 |
| Today's Move | -Rs 82.45 (-2.3%) |
| Open | Rs 3,560.65 |
| High | Rs 3,581.4 |
| Low | Rs 3,498.5 |
| Market Capitalisation | Rs 44,762.82 crore |
Ajanta Pharma Share Price Fall Streak moved through a wide intraday band before settling near the lower end of the day’s range. The stock opened at Rs 3,560.65, touched a high of Rs 3,581.4 and a low of Rs 3,498.5, before last trading at Rs 3,499.75. That leaves the stock Rs 82.45 below the previous close of Rs 3,582.2, matching a 2.3% decline for the day. The share price also stayed very close to the day’s low, which shows where the market left it as the session progressed.
Ajanta Pharma Share Price Fall Streak therefore reflects more than a routine fluctuation: the stock is now down for the second straight session, and the cumulative fall from the streak start base price of Rs 3,617.45 stands at 3.25%. With a market capitalisation of Rs 44,762.82 crore and the company in the Large Cap category, the move is important for investors following Ajanta Pharma Share Price Today. The next read comes from fundamentals.
What the Consecutive Declines Show
Ajanta Pharma Share Price Fall Streak is the central story here because the market is not reacting to just one session in isolation. A second straight lower close means the current price has moved away from the streak start base price of Rs 3,617.45 by 3.25% across the run, while the one-day change of Rs 82.45 shows how much of that move came in the latest session. For Ajanta Pharma Share Price, the cumulative read is now more useful than the day-by-day change.
The latest lower close also places Ajanta Pharma Share Price Fall Streak in a cleaner context for stock analysis. The current price, the previous close, and the lower close in succession show a pattern that readers can track without guessing a cause. According to latest Univest figures, the price pattern is confirmed, but the streak itself does not establish a company-specific reason.
Ajanta Pharma (AJANTPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 44,762.82 crore |
| P/E Ratio | 39.44x |
| P/B Ratio | 9.21x |
| ROE | 25.42% |
| ROCE | 32.67% |
| EPS | Rs 90.82 |
| Book Value Per Share | Rs 388.77 |
| Dividend Yield | 0.78% |
Ajanta Pharma (AJANTPHARM) fundamental metrics show P/E 39.44x, P/B 9.21x, ROE 25.42%, ROCE 32.67%. These ratios show where the company stands today and are not a call to buy or sell.
Ajanta Pharma has a market capitalisation of Rs 44,762.82 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 39.44x, P/B at 9.21x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 25.42% and ROCE of 32.67%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 90.82, book value per share of Rs 388.77, dividend yield of 0.78%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.94x, median ROE of 11.53%, median ROCE of 13.24%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 39.44x |
| Benchmark Median P/E | 31.94x |
| Benchmark Average P/E | 48.28x |
| Benchmark P/E Range | 3.58x to 685.2x |
| Company P/B Ratio | 9.21x |
| Benchmark Median P/B | 2.88x |
| Benchmark Average P/B | 4.3x |
| Company ROE | 25.42% |
| Benchmark Median ROE | 11.53% |
| Benchmark Average ROE | 10.04% |
| Company ROCE | 32.67% |
| Benchmark Median ROCE | 13.24% |
| Benchmark Average ROCE | 12.82% |
| Company Market Capitalisation | Rs 44,762.82 crore |
| Benchmark Median Market Cap | Rs 732.17 crore |
| Benchmark Average Market Cap | Rs 13,776.13 crore |
Ajanta Pharma (AJANTPHARM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Ajanta Pharma (AJANTPHARM) has a P/E ratio of 39.44x, which is above the benchmark median of 31.94x, a difference of +23.48%. A P/E difference of this kind is a reference point rather than a recommendation.
Ajanta Pharma (AJANTPHARM) has a ROE of 25.42%, which is above the benchmark median of 11.53%, a difference of +120.47%. Ajanta Pharma (AJANTPHARM) has a ROCE of 32.67%, which is above the benchmark median of 13.24%, a difference of +146.75%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,34,279.63 | 35.9 | 5.02 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,46,737.12 | 84.35 | 13.97 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,81,129.27 | 83.05 | 20.18 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,14,239.13 | 25.31 | 4.24 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,08,808.05 | 32.28 | 3.1 | 11.83 | 16 |
Ajanta Pharma (AJANTPHARM) has a P/E ratio of 39.44x compared with the displayed peer median of 35.9x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 25.42% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 32.67% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Ajanta Pharma (AJANTPHARM) has a market capitalisation of Rs 44,762.82 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Ajanta Pharma
- Ajanta Pharma Share Price Fall Streak shows a second straight lower close, which keeps short-term price action in focus.
- The latest Ajanta Pharma Share Price remains close to the day’s low, making the intraday path important for readers tracking Ajanta Pharma Stock News.
- Ajanta Pharma Fundamental Analysis still shows a high ROE of 25.42% and ROCE of 32.67% after the decline.
- The P/E of 39.44 and P/B of 9.21 keep Ajanta Pharma Share Price under valuation scrutiny versus the healthcare benchmark.
- Ajanta Pharma Market Cap of Rs 44,762.82 crore places it in the Large Cap bracket while the streak remains the main market update.
About Ajanta Pharma
Ajanta Pharma works in the Pharmaceuticals & Drugs industry within Healthcare. For readers following Ajanta Pharma Share Price Fall Streak, the business context matters because the stock is reacting while the core company profile remains unchanged. The company’s business positioning is relevant mainly through its valuation, return ratios and industry standing, not through any fresh operational shift visible in today’s price data.
Ajanta Pharma Share Price today therefore sits within a large pharmaceutical franchise that is being judged through market cap, returns and peer comparison. That is the practical lens for Ajanta Pharma Stock Performance in this streak.
Track Ajanta Pharma Share Price on Univest
Use Ajanta Pharma (AJANTPHARM) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Readers can track Ajanta Pharma Share Price, Ajanta Pharma Share Price Today, key valuation ratios, 52-week levels and market insights on Univest. Ajanta Pharma Share Price Fall Streak can be followed alongside broader Ajanta Pharma Stock Analysis, company fundamentals and healthcare sector context in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Ajanta Pharma Share Price falling today?
Ans. Ajanta Pharma Share Price is lower again in a second straight session, but the verified price data does not establish a company-specific cause. The move is confirmed through the latest close, the day’s fall and the cumulative streak change.
How much has Ajanta Pharma Share Price fallen in the streak?
Ans. Ajanta Pharma Share Price Fall Streak shows a cumulative decline of 3.25% from the streak start base price of Rs 3,617.45. The latest session added a Rs 82.45 decline, taking the stock to Rs 3,499.75.
What was the previous close for Ajanta Pharma Share Price?
Ans. The previous close for Ajanta Pharma Share Price was Rs 3,582.2. The stock last traded at Rs 3,499.75, which means the latest move was Rs 82.45 lower and kept the streak in place.
What does Ajanta Pharma Share Price Fall Streak mean for investors?
Ans. It means the stock has now posted two straight lower closes, so the pattern is more meaningful than a single-day move. Investors usually watch the price path, valuation ratios and sector comparison after such a streak.
How is Ajanta Pharma valued after the decline?
Ans. Ajanta Pharma Share Price trades on a P/E of 39.44 and a P/B of 9.21 after the decline. The earnings base and book-value base are unchanged, so the lower price is what shifts the multiples.
How does Ajanta Pharma compare with the healthcare industry?
Ans. Ajanta Pharma Share Price remains above the industry P/E median of 31.94 and above the P/B median of 2.88. Its ROE of 25.42% and ROCE of 32.67% also stand above the benchmark medians.
Is Ajanta Pharma a Large Cap company?
Ans. Yes. Ajanta Pharma Share Price is associated with a Large Cap company and a market capitalisation of Rs 44,762.82 crore. That size context matters when comparing it with smaller healthcare peers and industry benchmarks.
What should readers watch next in Ajanta Pharma Share Price?
Ans. Readers should watch whether Ajanta Pharma Share Price stabilises after the second straight session of decline, how it trades against the previous close, and whether valuation remains elevated versus the healthcare benchmark and peer set.
Recent Articles

Accenture Q4 Results Decoded: How a Strong Show and a 3% to 6% FY27 Outlook Affect Indian IT Stocks TCS, Infosys, Wipro, HCL Tech and Tech Mahindra, and What Experts Say
5 October 2026

IT Stocks to Buy Ahead of Q2 Results: TCS, HCL Tech and Mphasis Target Prices, Upside and Preview as Brokerages Split Between Buy, Add and Reduce
5 October 2026

Sobha Share Price in Focus: Record H1 FY27 Pre-Sales of Rs 5,862 Crore Put the 30% Growth Guidance Within Reach, but a 40% Quarterly Dip Keeps Investors Cautious
5 October 2026

Hero Motors Share Price Up 20% in a Third Straight Upper Circuit: What Is Driving the Stock After a Weak Debut, With Target, Stop-Loss, Valuation and the Latest Update
5 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Accenture Q4 Results Decoded: How a Strong Show and a 3% to 6% FY27 Outlook Affect Indian IT Stocks TCS, Infosys, Wipro, HCL Tech and Tech Mahindra, and What Experts Say
IT Stocks to Buy Ahead of Q2 Results: TCS, HCL Tech and Mphasis Target Prices, Upside and Preview as Brokerages Split Between Buy, Add and Reduce
Sobha Share Price in Focus: Record H1 FY27 Pre-Sales of Rs 5,862 Crore Put the 30% Growth Guidance Within Reach, but a 40% Quarterly Dip Keeps Investors Cautious
Hero Motors Share Price Up 20% in a Third Straight Upper Circuit: What Is Driving the Stock After a Weak Debut, With Target, Stop-Loss, Valuation and the Latest Update
New IPO Listings on 5 October: Discount or Premium? Orient Cables Surges 65%, AceVector (Snapdeal) Falls 11.5%, Runwal Enterprises Lists Flat and German Green Steel & Power Gains 2%

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





